One study further highlighted the prognostic value of the presence of CD137 on circulating CD8+ T cells in resected stage 3 melanoma patients after adjuvant ipilimumab + nivolumab combination therapy [22]. The gene discussed is TNFRSF9; the disease is melanoma.